Feb 20, 2015 ... application/pdf icon FTC v. Boehringer Ingelheim Pharmaceuticals, Inc. (D.C. Cir.
), Response of FTC to Petition for Rehearing En Banc (113.12 ...
www.leagle.com/decision/1995235234Conn1_1235/TOROSYAN v. BOEHRINGER INGELHEIM PHARMACEUTICALS, INC.
Lawyer, Attorney, Counsel, Law Firm, & then ANUSHAVAN G. TOROSYAN v. ...
action alleging that the defendant, Boehringer Ingelheim Pharmaceuticals, Inc...
Boehringer Ingelheim International GmbH has agreed to pay roughly $650
million to settle claims in multidistrict ... Richard W Cohen, Lowey Dannenberg et
Oct 28, 2015 ... Coleman et al derived such a multivariable benchmarking rule for in-hospital ....
performed using SAS V.9.2 (SAS Institute Inc, Cary, North Carolina, USA) or ....
Berlin, Germany; and Boehringer-Ingelheim Pharmaceuticals, Inc, ...
Mar 15, 2016 ... COOK COUNTY, et al., Defendants–Appellees. ... Coleman v. ..... Boehringer
Ingelheim Pharmaceuticals, Inc., 627 F.3d 596, 601 (7th Cir.2010) ...
rivaroxaban vs prior VKA) for ACTS burden and benefit scores were calculated ...
Boehringer Ingelheim Pharmaceuticals Inc., Daiichi Sankyo Company, and
Portola Pharmaceuticals. .... C. Coleman et al: Rivaroxaban and patient
Performance Plumbing of Southwest Florida, Inc. et al. Date: December 29, 2015
.... Absolute Activist Value Master Fund Limited et al v. Devine Date: December ...
Peters v. Boehringer-Ingelheim Pharmaceuticals, Inc. ... Coleman v. Starbucks
Oct 17, 2016 ... A. Schwarzenegger et al. v. M. Plata and R. Coleman, et al. J.D.B. v. State of ... at
Austin, et al. Boehringer Ingelheim Pharmaceuticals, Inc. v.
Apr 1, 2016 ... Keywords: Apixaban, Atrial fibrillation, Drug prescriptions, .... relative (0.6%
absolute) higher use of reduced dose rivaroxaban vs. .... Boehringer-Ingelheim
Pharmaceuticals Inc., Bayer Pharma A.G., ... Craig I. Coleman et al.
Apr 28, 2015 ... All agents significantly reduced HbA1c vs. placebo; albeit not to the same ...
Citation: Mearns ES, Sobieraj DM, White CM, Saulsberry WJ, Kohn CG, Doleh Y,
et al. ... Funding: This work was supported by Boehringer Ingelheim
Pharmaceuticals, Inc. (BIPI). ...... Phung OJ, Scholle JM, Talwar M, Coleman CI.